Statements (58)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:administered_by |
gptkb:children
|
| gptkbp:approves |
gptkb:2015
gptkb:European_Medicines_Agency |
| gptkbp:clinical_trial |
gptkb:Africa
over 15,000 Phase III trials |
| gptkbp:contains |
Plasmodium falciparum antigens
|
| gptkbp:defense |
recommended for pilot implementation
|
| gptkbp:developed_by |
gptkb:Glaxo_Smith_Kline
|
| gptkbp:development |
gptkb:2001
|
| gptkbp:doses_recommended |
four doses
|
| gptkbp:first_dose_age |
6 weeks
|
| gptkbp:fourth_dose_age |
18 months
|
| gptkbp:funding |
PATH Malaria Vaccine Initiative
|
| https://www.w3.org/2000/01/rdf-schema#label |
Mosquirix
|
| gptkbp:is_effective_against |
approximately 30%
|
| gptkbp:is_recommended_for |
high-risk populations
|
| gptkbp:is_vulnerable_to |
gptkb:supply_chain_management
refrigerated public acceptance ongoing studies distribution logistics healthcare infrastructure improves quality of life cold chain requirements preventive vaccine access in remote areas reduces mortality rates reduces hospitalizations reduces severe malaria cases cost of vaccination programs enhances immunity limited efficacy need for booster doses promotes herd immunity protects against malaria infection reduces malaria transmission |
| gptkbp:marketed_as |
RTS, S/ AS01
|
| gptkbp:partnerships |
gptkb:Bill_&_Melinda_Gates_Foundation
|
| gptkbp:route_of_administration |
intramuscular injection
|
| gptkbp:second_dose_age |
10 weeks
|
| gptkbp:side_effect |
fever
irritability pain at injection site loss of appetite sleepiness |
| gptkbp:targets |
malaria
|
| gptkbp:third_dose_age |
14 weeks
|
| gptkbp:type |
subunit vaccine
|
| gptkbp:vaccine_future |
expansion to other regions
collaboration with global health organizations integration with other vaccines potential for new formulations research for improved efficacy |
| gptkbp:vaccine_shelf_life |
up to 24 months
|
| gptkbp:bfsParent |
gptkb:GSK
|
| gptkbp:bfsLayer |
4
|